• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Complications of switching from anti-IL-5 or anti-IL-5R to dupilumab in corticosteroid-dependent severe asthma.

作者信息

Eger Katrien, Pet Lodewijk, Weersink Els J M, Bel Elisabeth H

机构信息

Department of Respiratory Medicine, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.

Department of Respiratory Medicine, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.

出版信息

J Allergy Clin Immunol Pract. 2021 Jul;9(7):2913-2915. doi: 10.1016/j.jaip.2021.02.042. Epub 2021 Mar 4.

DOI:10.1016/j.jaip.2021.02.042
PMID:33676050
Abstract
摘要

相似文献

1
Complications of switching from anti-IL-5 or anti-IL-5R to dupilumab in corticosteroid-dependent severe asthma.在依赖皮质类固醇的重度哮喘患者中，从抗IL-5或抗IL-5R转换为度普利尤单抗治疗的并发症。
J Allergy Clin Immunol Pract. 2021 Jul;9(7):2913-2915. doi: 10.1016/j.jaip.2021.02.042. Epub 2021 Mar 4.
2
Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.奥马珠单抗可作为严重哮喘中慢性口服皮质类固醇替代疗法。
Respir Med. 2019 Apr;150:51-62. doi: 10.1016/j.rmed.2019.02.003. Epub 2019 Feb 7.
3
Biologics for oral corticosteroid-dependent asthma.用于口服皮质类固醇依赖型哮喘的生物制剂。
Allergy Asthma Proc. 2020 May 1;41(3):151-157. doi: 10.2500/aap.2020.41.200015.
4
Dupilumab: A Review in Moderate to Severe Asthma.度普利尤单抗：中重度哮喘的治疗药物。
Drugs. 2019 Nov;79(17):1885-1895. doi: 10.1007/s40265-019-01221-x.
5
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.度普利尤单抗治疗伴有鼻息肉的重度慢性鼻-鼻窦炎患者的疗效和安全性（LIBERTY NP SINUS-24 和 LIBERTY NP SINUS-52）：两项多中心、随机、双盲、安慰剂对照、平行分组 3 期临床试验的结果。
Lancet. 2019 Nov 2;394(10209):1638-1650. doi: 10.1016/S0140-6736(19)31881-1. Epub 2019 Sep 19.
6
Dupilumab Improves Asthma Control and Lung Function in Patients with Insufficient Outcome During Previous Antibody Therapy.度普利尤单抗改善既往抗体治疗应答不足患者的哮喘控制和肺功能。
J Allergy Clin Immunol Pract. 2021 Mar;9(3):1177-1185.e4. doi: 10.1016/j.jaip.2020.09.014. Epub 2020 Sep 24.
7
Matching-adjusted comparison of oral corticosteroid reduction in asthma: Systematic review of biologics.哮喘中口服皮质类固醇减量的匹配调整比较：生物制剂的系统评价。
Clin Exp Allergy. 2020 Apr;50(4):442-452. doi: 10.1111/cea.13561. Epub 2020 Mar 20.
8
Anti-IL-4/IL-13 for the treatment of asthma: the story so far.抗 IL-4/IL-13 治疗哮喘：迄今为止的故事。
Expert Opin Biol Ther. 2020 Mar;20(3):283-294. doi: 10.1080/14712598.2020.1714027. Epub 2020 Jan 20.
9
[Biological Treatments in patients with ABPA].[变应性支气管肺曲霉菌病患者的生物治疗]
Tuberk Toraks. 2021 Mar;69(1):84-93. doi: 10.5578/tt.20219910.
10
[CME: Mepolizumab, an Additional Therapeutic Agent for Severe Asthma].[继续医学教育：美泊利单抗，重度哮喘的一种额外治疗药物]
Praxis (Bern 1994). 2018;107(21):1129-1135. doi: 10.1024/1661-8157/a003076.

引用本文的文献

1
Long-term outcomes of dupilumab therapy in severe asthma: A retrospective, multicenter, real-world study.度普利尤单抗治疗重度哮喘的长期疗效：一项回顾性、多中心、真实世界研究。
J Allergy Clin Immunol Glob. 2025 Jul 8;4(4):100533. doi: 10.1016/j.jacig.2025.100533. eCollection 2025 Nov.
2
Real world evidence of dupilumab effectiveness in a Colombian cohort of patients diagnosed with severe asthma.度普利尤单抗在哥伦比亚一组重度哮喘确诊患者中的真实世界疗效证据。
Front Allergy. 2025 May 13;6:1564033. doi: 10.3389/falgy.2025.1564033. eCollection 2025.
3
Early Intervention with Mepolizumab, Corticosteroids, and Intravenous Immunoglobulin for Dupilumab-Triggered Eosinophilic Granulomatosis with Polyangiitis: A Case Report.
美泊利珠单抗、皮质类固醇和静脉注射免疫球蛋白对度普利尤单抗引发的嗜酸性肉芽肿性多血管炎的早期干预：一例报告
J Asthma Allergy. 2025 Apr 13;18:559-565. doi: 10.2147/JAA.S513640. eCollection 2025.
4
Biologics for Chronic Rhinosinusitis With Nasal Polyps: Current Status and Clinical Considerations in Korea.用于伴鼻息肉的慢性鼻-鼻窦炎的生物制剂：韩国的现状与临床考量
J Rhinol. 2025 Mar;32(1):1-9. doi: 10.18787/jr.2025.00002. Epub 2025 Mar 21.
5
Case Report: Dual monoclonal antibody therapy in chronic rhinosinusitis with nasal polyps and severe eosinophilic asthma-a proteome analysis.病例报告：双单克隆抗体疗法治疗伴有鼻息肉的慢性鼻-鼻窦炎和重度嗜酸性粒细胞性哮喘——蛋白质组分析
Front Allergy. 2024 Nov 1;5:1484931. doi: 10.3389/falgy.2024.1484931. eCollection 2024.
6
Tralokinumab as an Alternative to Dupilumab in a Patient with Atopic Dermatitis and Asthma who Developed Hypereosinophilia: A Case Report.特应性皮炎和哮喘患者发生嗜酸性粒细胞增多症时，曲罗芦单抗作为度普利尤单抗的替代药物：一例报告
Acta Derm Venereol. 2024 Sep 19;104:adv40800. doi: 10.2340/actadv.v104.40800.
7
The Possible Roles of IL-4/IL-13 in the Development of Eosinophil-Predominant Severe Asthma.IL-4/IL-13 在嗜酸性粒细胞为主的重症哮喘发病中的可能作用
Biomolecules. 2024 May 2;14(5):546. doi: 10.3390/biom14050546.
8
Advancing Care in Severe Asthma: The Art of Switching Biologics.推进重症哮喘护理：生物制剂转换的艺术。
Adv Respir Med. 2024 Feb 21;92(2):110-122. doi: 10.3390/arm92020014.
9
[Eosinophils in otorhinolaryngology: friend or foe?].[耳鼻喉科中的嗜酸性粒细胞：朋友还是敌人？]
HNO. 2024 Apr;72(4):242-249. doi: 10.1007/s00106-024-01442-x. Epub 2024 Mar 4.
10
Clinical Remission in Patients Affected by Severe Eosinophilic Asthma on Dupilumab Therapy: A Long-Term Real-Life Study.度普利尤单抗治疗重度嗜酸性粒细胞性哮喘患者的临床缓解：一项长期真实世界研究
J Clin Med. 2024 Jan 4;13(1):291. doi: 10.3390/jcm13010291.